Learn about INVOKANA®, an SGLT2 inhibitor that helps lower blood sugar and risk of cardiovascular disease in adults. See full Prescribing & Safety Info. INVOKANA is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an INVOKANA mg once daily who have an eGFR of 60 mL/min/ m2. INVOKANA® is now the only oral diabetes treatment approved to in the INVOKANA® U.S. full Prescribing Information (PI).3 The PI also.

Author: Zulurisar Goltizshura
Country: Iraq
Language: English (Spanish)
Genre: Marketing
Published (Last): 27 October 2013
Pages: 468
PDF File Size: 12.76 Mb
ePub File Size: 18.57 Mb
ISBN: 873-8-74404-751-9
Downloads: 6541
Price: Free* [*Free Regsitration Required]
Uploader: Vudokree

View all slides as one page. To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions. Avoid co-administration with CYP2D6 substrates with a narrow therapeutic index.

Invokana Insights: 10 Drug-Specific Facts You Should Know

Discontinue following the completion of a chemotherapy invo,ana. The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Appropriate diagnostic testing should be considered, e.

Metformin Hypoglycemia does not occur in patients receiving metformin alone under usual circumstances of use, but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or when used concomitantly with other glucose-lowering agents such as sulfonylureas or insulin or ethanol.

If needed, Janssen, the manufacturer of Invokana, may be able to offer cost assistance for Invokana if you qualify. Therefore, caution should be exercised in patients receiving or who invokan received allergen immunotherapy, particularly for anaphylaxis. The SGLT2 inhibitors block the kidney from reabsorbing sugar glucose. Plus, patients should talk to their involana about factors that may increase their risk for bone inokana.

Consider medication with antihistamines, acetaminophen, and corticosteroids. Most infusion reactions occurred during the first infusion and were grade The published trials presented in the submission are shown in the following table: Subscribe to free Drugs. Renal impairment, including cases of acute renal failure and Fanconi syndrome, invvokana been reported with the use of tenofovir prodrugs.


Neutropenic sepsis, including fatal cases, can occur.

Economic Analysis The submission presented a cost-minimisation analysis, based on non-inferiority claim of canagliflozin mg to sitagliptin mg for mean reduction in HbA1c from baseline. Who Should Not Use Invokana? The PBAC did not consider this claim to be reasonable, agreeing that infections could be more common in non-trial populations, and considered that the cost of managing infections related to treatment should be accounted for. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs eg, carbonic anhydrase inhibitors such as topiramateage 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states eg, acute congestive heart failureexcessive alcohol intake, and hepatic impairment.

The sponsor also claimed that such cases would be managed with over-the-counter treatments, and that therefore higher infection rates would not be associated with increased cost to government.

Invokana should not be used to treat a condition called diabetic ketoacidosiswhich is a potentially deadly complication of diabetes when you do not have enough insulin. Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia some fatal have been reported.

The PBAC noted that while the overall rates of adverse events associated with canagliflozin and sitagliptin treatment were similar, there was a higher rate of genital mycotic infections in canagliflozin treatment groups.

Indication and Important Safety Information

Stop the infusion if the patient develops signs of anaphylaxis. Promptly measure serum total bilirubin, AST, and ALT if clinical symptoms or signs suggestive of hepatotoxicity develop. The malignancies occurred after a median of 30 months after the first dose of therapy. To view content sources and attributions, please refer to our editorial policy.

  LEGO 8421 PDF

Median time to complete resolution was 14 days range: The PBAC therefore considered that canagliflozin was non-inferior to sitagliptin with respect to efficacy. Symptoms of infusion reactions consisted of back pain, chest pain or discomfort, nausea and vomiting, flushing, erythema, and palpitations.

Canagliflozin, tablet, 100 mg and 300 mg, Invokana® – July 2013

Please refer to the ritonavir prescribing information for additional safety information. The FDA stated that patients who experience signs or symptoms of ketoacidosis such as trouble breathing, nausea, vomiting, abdominal [stomach] pain, confusion, unusual fatigue or sleepiness should contact their doctor immediately to determine if they have ketoacidosis, as your drug treatment may need to be stopped. The submission also included a supplementary comparison with dapagliflozin, a pharmacological analogue of canagliflozin.

Signs of low blood sugar include: Serious infections and fatal outcomes have been invokzna in such patients.

Interrupt infusion imvokana reactions of any severity and institute medical management as needed. Like most other medicines, Invokana has important drug interactions you should be aware of.

Counsel patients about the importance of routine preventative foot care. Short follow-up periods, such as those of 1 year or less in the studies above, may not adequately reflect the true incidence of malignancies. The PBAC noted no statistically significant differences in the head to head trials and indirect comparisons between canagliflozin and sitagliptin in terms of patients with at least one adverse event, with at least one serious adverse event and with adverse events leading to discontinuation.

Public Summary Document Product: Published trial for Canagliflozin Hermansen, K et al.